Home LiteratureArticle Details
PMID: 2845130 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Journal of virology ·Vol. 62 ·No. 11 ·1988-11-00 ·Pages 4195-200

Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, Matthews TJ

Abstract

Animals immunized with the human immunodeficiency virus type 1 gp160 glycoprotein or certain recombinant envelope components develop potent virus-neutralizing activity. This activity is principally due to antibodies directed toward a hypervariable region of gp120 between cysteine residues 302 and 337 and is virus isolate specific. These antisera, as well as two neutralizing monoclonal antibodies directed against the same hypervariable sequence, do not appreciably block gp120 from binding CD4. In contrast, serum samples from infected humans possess high titers of antibodies that block gp120-CD4 binding; these titers approximately correlate with the serum neutralization titers. Our results suggest that there are at least two targets on the envelope glycoprotein for virus neutralization. The target responsible for the broader neutralizing activity of human serum may be a conserved region of gp120 involved in CD4 binding. The antibodies directed at the hypervariable region of the envelope inhibit a different step in virus infection which is subsequent to receptor binding. The extent to which these two different epitopes of gp120 may be involved in protection against human immunodeficiency virus infection is discussed.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology Antibody Affinity Cell Fusion Cells, Cultured HIV Antibodies/physiology HIV Envelope Protein gp120 HIV Envelope Protein gp160 Humans Immune Sera/immunology Immunization Neutralization Tests Receptors, HIV Receptors, Virus/immunology Retroviridae Proteins/immunology Viral Envelope Proteins/immunology
Chemicals
HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp160 Immune Sera Receptors, HIV Receptors, Virus Retroviridae Proteins Viral Envelope Proteins
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Skinner M A
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Langlois A J
McDanal C B
McDougal J S
Bolognesi D P
Matthews T J
References (37)
37 references, click to expand
  1. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.
    J Natl Cancer Inst. 1972 Sep;49(3):891-5 PMID: 4567231
  2. Neutralizing monoclonal antibodies to the AIDS virus.
    AIDS. 1988 Feb;2(1):25-9 PMID: 2451922
  3. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
    Science. 1984 May 4;224(4648):497-500 PMID: 6200935
  4. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
    Science. 1986 Dec 12;234(4782):1392-5 PMID: 2431482
  5. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  6. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  7. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  8. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.
    AIDS Res Hum Retroviruses. 1988 Jun;4(3):187-97 PMID: 2456088
  9. Mechanisms of neutralization of animal viruses.
    J Gen Virol. 1984 Jun;65 ( Pt 6):1015-22 PMID: 6202836
  10. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  11. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  12. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.
    Nature. 1985 Jul 4-10;316(6023):69-72 PMID: 2989706
  13. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.
    Nature. 1985 Jul 4-10;316(6023):72-4 PMID: 2989707
  14. Genomic diversity of human T-lymphotropic virus type III (HTLV-III).
    Science. 1985 Aug 23;229(4715):759-62 PMID: 2992084
  15. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.
    Science. 1986 Jan 24;231(4736):382-5 PMID: 3001934
  16. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.
    Science. 1986 May 30;232(4754):1135-7 PMID: 3010464
  17. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
    Cell. 1986 Jun 6;45(5):637-48 PMID: 2423250
  18. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients.
    Cell. 1986 Jul 4;46(1):63-74 PMID: 2424612
  19. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.
    Science. 1986 Jul 11;233(4760):209-12 PMID: 3014647
  20. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):7023-7 PMID: 3018753
  21. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.
    J Immunol. 1986 Nov 1;137(9):2937-44 PMID: 2428879
  22. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Nature. 1986 Dec 11-17;324(6097):572-5 PMID: 2431324
  23. Induction of anti-HIV neutralizing antibodies by synthetic peptides.
    EMBO J. 1986 Nov;5(11):3065-71 PMID: 3466790
  24. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709-13 PMID: 2432599
  25. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
    J Virol. 1987 Jun;61(6):2024-8 PMID: 2437327
  26. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.
    Cell. 1987 Jun 5;49(5):659-68 PMID: 3107838
  27. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia.
    J Immunol. 1987 Jun 1;138(11):3731-6 PMID: 3495568
  28. Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.
    Proc Natl Acad Sci U S A. 1987 Aug;84(15):5424-8 PMID: 3037551
  29. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.
    Cell. 1987 Jul 31;50(3):327-8 PMID: 3496970
  30. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.
    Cell. 1987 Sep 11;50(6):975-85 PMID: 2441877
  31. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    J Virol. 1987 Oct;61(10):3173-80 PMID: 2442411
  32. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
    Science. 1987 Sep 11;237(4820):1351-5 PMID: 3629244
  33. Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.
    Proc Natl Acad Sci U S A. 1987 Oct;84(19):6924-8 PMID: 3477816
  34. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
    Science. 1988 Feb 26;239(4843):1021-3 PMID: 2830667
  35. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  36. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.
    Proc Natl Acad Sci U S A. 1988 Apr;85(8):2815-9 PMID: 3357892
  37. A practical computer-based approach to the analysis of radioligand binding experiments.
    Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107-13 PMID: 6319079
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.62.11.4195-4200.1988
Published
1988-11-00
Pages
4195-200
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC253851
Subset
IM
Grants
NCI NIH HHS · 5PO1-CA43447-03 · United States
NIH HHS · FOD-0758 · United States
External Links
PubMed source DOI: 10.1128/JVI.62.11.4195-4200.1988 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2